Balyasny Asset Management LLC Fibrogen Inc Transaction History

Balyasny Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.89 - $2.36 $17,259 - $45,767	19,393 New	19,393 $17,000
Q3 2023 Nov 14, 2023	SELL	$0.79 - $2.83 $220,742 - $790,761	-279,421 Reduced 74.34%	96,451 $82,000
Q2 2023 Aug 14, 2023	BUY	$2.49 - $20.59 $866,091 - $7.16 Million	347,828 Added 1240.29%	375,872 $1.01 Million
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $447,301 - $706,147	28,044 New	28,044 $523,000
Q1 2022 May 16, 2022	SELL	$12.02 - $16.79 $134,744 - $188,215	-11,210 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$9.93 - $15.39 $111,315 - $172,521	11,210 New	11,210 $158,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.